home All News open_in_new Full Article

PharmaMar duplica su beneficio neto hasta los 15,3 millones hasta septiembre

La empresa ha registrado unos ingresos totales de 130,9 millones de euros, un 3% más. Más información:Sylentis (PharmaMar) recibirá una subvención de 21,1 millones de los fondos Next Generation


today 3 w. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 589411901
Add Watch Country

arrow_drop_down